Brie Carter

Crypto trading firm Wintermute has expanded into prediction markets, aiming to provide liquidity across event-based contracts as the sector experiences rapid growth.

Greenwich LifeSciences (NASDAQ:GLSI) reported new open-label immune response data from its ongoing Phase III FLAMINGO-01 clinical trial evaluating its lead immunotherapy candidate, GLSI-100, in patients with HER2-positive breast cancer.

A $1.26 billion block trade in BlackRock’s iShares Bitcoin Trust last week was likely a large investor exiting a concentrated Bitcoin position rather than unwinding a market-neutral strategy, according to NYDIG.

AstraZeneca (NASDAQ:AZN) unveiled positive data from its late-stage EMERALD-3 clinical trial on Monday, demonstrating that adding its dual-immunotherapy regimen to standard localized therapy significantly slows disease progression in patients battling early-stage, unresectable liver cancer.

Citius Oncology (NASDAQ:CTOR) showcased positive early-stage clinical trial results, demonstrating the potential of its targeted immune therapy LYMPHIR to enhance the efficacy of checkpoint inhibitors in treating recurrent or refractory gynecologic cancers.

A7 executive Stanislav Lazarev said growing sanctions pressure from Western countries is driving Russia toward alternative cross-border payment systems, including digital assets and stablecoins.

Parsons (NYSE:PSN) announced Monday that it has been awarded a $99 million single-award task order from the U.S. Air Force Research Laboratory (AFRL) to expand its development of advanced tactical command and control systems alongside space-based intelligence architectures.

Kalshi chief executive Tarek Mansour is trying to build a regulated exchange that turns real-world questions into tradable markets.

Ripple's Middle East and Africa managing director Reece Merrick said Turkey has emerged as the leading cryptocurrency market in the Middle East and North Africa, recording approximately $200 billion in crypto transaction volume over the past year.

Agios Pharmaceuticals (NASDAQ:AGIO) has acquired an exclusive global license for Oscotec's cevidoplenib, an experimental oral treatment for a rare blood disorder, betting the asset can capture up to $1 billion in peak U.S. sales despite recently missing the main goal of a mid-stage trial.